title: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
abstract: On August 13, 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) among adults aged ≥65 years. PCV13 should be administered in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax23, Merck & Co., Inc.]), the vaccine currently recommended for adults aged ≥65 years. PCV13 was approved by the Food and Drug Administration (FDA) in late 2011 for use among adults aged ≥50 years. In June 2014, the results of a randomized placebo-controlled trial evaluating efficacy of PCV13 for preventing community-acquired pneumonia among approximately 85,000 adults aged ≥65 years with no prior pneumococcal vaccination history (CAPiTA trial) became available and were presented to ACIP. The evidence supporting PCV13 vaccination of adults was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and determined to be type 2 (moderate level of evidence); the recommendation was categorized as a Category A recommendation. This report outlines the new recommendations for PCV13 use, provides guidance for use of PCV13 and PPSV23 among adults aged ≥65 years, and summarizes the evidence considered by ACIP to make this recommendation.
authors.forename: Sara
authors.initials: S
authors.lastname: Tomczyk
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Bennett
authors.forename: Charles
authors.initials: C
authors.lastname: Stoecker
authors.forename: Ryan
authors.initials: R
authors.lastname: Gierke
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Moore
authors.forename: Cynthia G
authors.initials: CG
authors.lastname: Whitney
authors.forename: Stephen
authors.initials: S
authors.lastname: Hadler
authors.forename: Tamara
authors.initials: T
authors.lastname: Pilishvili
mesh_terms: D026683:Advisory Committees; D000368:Aged; D006801:Humans; D007115:Immunization Schedule; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D014481:United States / Q000453:epidemiology; D018074:Vaccines, Conjugate / Q000008:administration & dosage*
chemical_list: C538862:13-valent pneumococcal vaccine; C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate